We are live on ! Find out more
BCRX icon

BioCryst Pharmaceuticals
BCRX

120 hedge funds and large institutions have $439M invested in BioCryst Pharmaceuticals in 2017 Q3 according to their latest regulatory filings, with 22 funds opening new positions, 42 increasing their positions, 28 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more repeat investments, than reductions

Existing positions increased: 42 | Existing positions reduced: 28

29% more first-time investments, than exits

New positions opened: 22 | Existing positions closed: 17

14% more capital invested

Capital invested by funds: $384M → $439M (+$54.6M)

4% more funds holding

Funds holding: 115 → 120 (+5)

1.07% less ownership

Funds ownership: 85.89% → 84.81% (-1.1%)

50% less funds holding in top 10

Funds holding in top 10: 4 → 2 (-2)

77% less call options, than puts

Call options by funds: $1.1M | Put options by funds: $4.83M

Holders
120
Holders Change
+5
Holders Change %
+4.35%
% of All Funds
2.99%
Holding in Top 10
2
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-50%
% of All Funds
0.05%
New
22
Increased
42
Reduced
28
Closed
17
Calls
$1.1M
Puts
$4.83M
Net Calls
-$3.73M
Net Calls Change
-$7.98M

Top Buyers

Rank Fund Capital Flow
1
Janus Henderson Group
Janus Henderson Group
United Kingdom
+$23.2M
2
BBA
Baker Bros. Advisors
New York
+$11.7M
3
RCM
RA Capital Management
Massachusetts
+$9.33M
4
GPP
Great Point Partners
Connecticut
+$8.38M
5
DM
Deerfield Management
New York
+$7.56M

Top Sellers

Rank Fund Capital Flow
1
State Street
State Street
Massachusetts
-$4.82M
2
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$3.05M
3
Goldman Sachs
Goldman Sachs
New York
-$2.89M
4
UONDDL
University of Notre Dame du Lac
Indiana
-$2.35M
5
PC
Paulson & Co
New York
-$1.94M
Name Holding Trade Value Shares
Change 		Change in
Stake
TRCT
101
Tower Research Capital (TRC)
New York
$50K +$45.3K +8,839 +1,473%
CG
102
Cutler Group
California
$44K -$18.2K -3,560 -30%
BNP Paribas Financial Markets
103
BNP Paribas Financial Markets
France
$43.3K -$2.99K -584 -7%
Royal Bank of Canada
104
Royal Bank of Canada
Ontario, Canada
$41K +$37.2K +7,259 +1,575%
Canada Life
105
Canada Life
Manitoba, Canada
$38K – – –
ASN
106
Advisory Services Network
Georgia
$34K – – –
AIP
107
Ameritas Investment Partners
Nebraska
$34K – – –
FPF
108
FNY Partners Fund
New York
$20K – – –
Zurich Cantonal Bank
109
Zurich Cantonal Bank
Switzerland
$9K – – –
Bank of Montreal
110
Bank of Montreal
Ontario, Canada
$5K – – –
IA
111
IFP Advisors
Florida
$5K – – –
AIM
112
Advantage Investment Management
Iowa
$3K – – –
SEI Investments
113
SEI Investments
Pennsylvania
$3K +$748 +146 +33%
AF
114
Allworth Financial
California
$3K +$2.56K +500 New
FMTCOCP
115
Farmers & Merchants Trust Co of Chambersburg PA
Pennsylvania
$2.62K – – –
LTFS
116
Ladenburg Thalmann Financial Services
Florida
$2K – – –
Envestnet Asset Management
117
Envestnet Asset Management
Illinois
$1K – – –
KF
118
Krilogy Financial
Missouri
$1K – – –
OC
119
Oakworth Capital
Alabama
$1K – – –
WAS
120
Winch Advisory Services
Wisconsin
$1K +$1.02K +200 New
UONDDL
121
University of Notre Dame du Lac
Indiana
– -$2.35M -422,767 Closed
PC
122
Paulson & Co
New York
– -$1.94M -349,500 Closed
JP Morgan Chase
123
JP Morgan Chase
New York
– -$1.36M -244,613 Closed
PP
124
PDT Partners
New York
– -$718K -129,200 Closed
Federated Hermes
125
Federated Hermes
Pennsylvania
– -$385K -69,320 Closed
2 3 4
5
6

BCRX Hedge Fund Activity: Q3 2017 in Review

120 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in BioCryst Pharmaceuticals (BCRX) for Q3 2017, worth a combined $439M — up 14% from $384M a quarter earlier.

Buyers outnumbered sellers: 22 funds opened new BCRX positions and 17 closed out — a net gain of 5 holders — while 42 added to existing stakes and 28 trimmed.

The largest buyer was Janus Henderson Group, opening a new position worth an estimated $23.2M. The largest seller was State Street, cutting an estimated $4.82M.

  • 120 institutional investors held BioCryst Pharmaceuticals (BCRX) as of Q3 2017, up from 115 in Q2 2017.
  • Funds reported $439M of BioCryst Pharmaceuticals stock for Q3 2017, up 14% quarter-over-quarter.
  • 22 funds opened new BioCryst Pharmaceuticals positions in Q3 2017 and 17 closed out, a net change of +5 holders.
  • The largest BioCryst Pharmaceuticals buyer in Q3 2017 was Janus Henderson Group, an estimated $23.2M added.
  • The largest BioCryst Pharmaceuticals seller in Q3 2017 was State Street, an estimated $4.82M sold.

Based on aggregated 13F filings for Q3 2017.